Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Jean-Baptiste TrouillerGeorgios F NikolaidisBérengère MacabeoNicolas MeyerLaetitia GerlierMax SchlueterPhilippe Laramee
Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2023)
EncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.